The primary objective of this investigation was to identify early changes in cMD during the disease trajectory and establish its relationship with Aβ and tau deposition, and alterations in cortical thickness across the cognitive continuum encompassing CN, MCI, and AD patients. This evidence concerns the gene MAPT and Alzheimer disease.